This week’s Rare Diseases update highlights regulatory momentum, late-stage clinical progress, commercial uptake, strategic dealmaking, and portfolio expansion across key orphan and specialty indications.
In Today’s Newsletter
Dive deeper
💼 Neurocrine Biosciences to buy Soleno, adds VYKAT XR [1] [US • 06 Apr 2026]
https://neurocrine.gcs-web.com/news-releases/news-release-details/neurocrine-acquire-soleno-therapeutics-expanding-its
Context: Soleno’s VYKAT XR (diazoxide choline) is FDA approved for hyperphagia in Prader-Willi syndrome, with 2025 revenue of $190 million.
Key point: Neurocrine Biosciences agreed to acquire Soleno Therapeutics for $53.00 per share in cash, valuing the deal at $2.9 billion.
Implication: Signals pipeline investment and modality expansion.
🧬 Abbisko wins EMA orphan status for irpagratinib in HCC [2] [EU • 01 Apr 2026]
https://www.biospace.com/press-releases/abbisko-therapeutics-fgfr4-inhibitor-irpagratinib-granted-orphan-drug-designation-by-ema-for-hepatocellular-carcinoma
Context: Irpagratinib (ABSK-011) is an oral FGFR4 inhibitor in studies for FGF19-overexpressing advanced hepatocellular carcinoma.
Key point: Abbisko Therapeutics said the EMA granted orphan drug designation to irpagratinib for hepatocellular carcinoma.
Implication: May influence prescriber choice and payer reviews pending full data.
💨 Precigen flags strong PAPZIMEOS launch momentum [3] [US • 07 Apr 2026]
https://www.biospace.com/press-releases/precigen-reports-robust-uptake-of-new-drug-for-rare-respiratory-disease-first-quarter-revenue-expected-to-top-18-million
Context: PAPZIMEOS (zopapogene imadenovec-drba) is approved in adults with recurrent respiratory papillomatosis, and CMS assigned J-code J3404 effective 01 Apr 2026.
Key point: Precigen said Q1 2026 revenue is expected to exceed $18 million, reflecting early uptake after the August 2025 launch.
Implication: Could streamline initiation and adherence via remote prescribing and logistics.
🧠 Shionogi completes RADICAVA rights acquisition [4] [01 Apr 2026]
https://www.businesswire.com/news/home/20260401952077/en/Shionogi-Completes-Acquisition-of-All-Rights-to-RADICAVA-edaravone
Context: RADICAVA (edaravone) is approved for amyotrophic lateral sclerosis, and Shionogi said more than 100 team members joined from Tanabe Pharma America.
Key point: Shionogi completed the transfer of all rights to RADICAVA in major countries and regions, under a deal previously announced at $2.5 billion.
Implication: Signals pipeline investment and modality expansion.
🦠 NanoViricides files rare pediatric disease application for NV-387 [5] [US • 07 Apr 2026]
https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/measles-rare-pediatric-disease-drug-designation-application-filed-for-1155499
Context: NanoViricides said NV-387 is being positioned for measles treatment, alongside an orphan drug designation application filed in February 2026.
Key point: The company filed a Rare Pediatric Disease Drug designation application with the FDA for NV-387 in measles.
Implication: May influence prescriber choice and payer reviews pending full data.
💉 Amgen reports positive Phase 3 topline for subcutaneous TEPEZZA [6] [US • 06 Apr 2026]
https://www.amgen.com/newsroom/press-releases/2026/04/amgen-announces-positive-topline-phase-3-results-for-subcutaneous-tepezza-in-adults-living-with-moderate-to-severe-active-thyroid-eye-disease
Context: In moderate-to-severe active thyroid eye disease, the study reported a 76.7% proptosis response rate for TEPEZZA OBI versus 19.6% for placebo, with mean proptosis reduction of -3.17 mm versus -0.80 mm at week 24.
Key point: Amgen said subcutaneous TEPEZZA met the primary endpoint and key secondary endpoint in Phase 3, with safety generally consistent with IV TEPEZZA.
Implication: May influence prescriber choice and payer reviews pending full data.
Why it matters
- Neurocrine’s Soleno acquisition adds an FDA-approved rare-disease asset and expands its endocrinology franchise [1].
- Abbisko’s EMA orphan status gives irpagratinib a clearer regulatory path in Europe for a biomarker-defined HCC population [2].
- Precigen’s PAPZIMEOS update suggests early commercial traction in RRP, with reimbursement support now in place via a CMS J-code [3].
- Shionogi’s RADICAVA integration gives it an established ALS product and operating base for broader rare-disease launches [4].
- Amgen’s subcutaneous TEPEZZA data could support a more convenient administration option in thyroid eye disease if regulators agree [6].
📚 View the full Rare Disease archive on our research hub page
🚀 Accelerate your success. Contact us now
📂 Explore our case studies. See examples of our work.
💡 Read our insights. Learn from our latest reports and analysis
🧰 See our full range of services. Discover how we can help you.
🎯 Catch up on the Top Rare Disease news from the past two weeks, curated by the LucidQuest team.
FAQ
What exactly is Neurocrine buying from Soleno?
Neurocrine Biosciences is acquiring Soleno Therapeutics, whose lead commercial asset is VYKAT XR (diazoxide choline), an FDA-approved treatment for hyperphagia in Prader-Willi syndrome. The announced equity value is $2.9 billion [1].
Why does EMA orphan designation matter for irpagratinib?
For Abbisko Therapeutics, EMA orphan drug designation can support development in Europe through incentives such as protocol assistance, fee reductions, and potential market exclusivity after approval. It does not mean the drug is approved yet [2].
What is driving attention around PAPZIMEOS?
Precigen says PAPZIMEOS is seeing strong early uptake in adult recurrent respiratory papillomatosis, with Q1 2026 revenue expected above $18 million. The company also highlighted a CMS J-code and plans in pediatrics and Europe [3].
What changes with Shionogi’s RADICAVA deal?
Shionogi now holds all rights to RADICAVA in major countries and regions, adding an established ALS medicine and rare-disease commercial infrastructure. The company said the integration was operational on day one [4].
Is NV-387 approved for measles treatment?
No. NanoViricides said it filed a Rare Pediatric Disease Drug designation application, and previously filed for orphan drug designation. This is a regulatory filing step, not an approval decision [5].
What did Amgen report for subcutaneous TEPEZZA?
Amgen reported positive Phase 3 topline results in active thyroid eye disease, including a statistically significant proptosis response and reduction in proptosis at week 24. Full results are still pending presentation [6].
Entities / Keywords
Neurocrine Biosciences, Soleno Therapeutics, VYKAT XR, diazoxide choline, Prader-Willi syndrome, PWS
Abbisko Therapeutics, irpagratinib, ABSK-011, FGFR4 inhibitor, hepatocellular carcinoma, HCC, FGF19-overexpressing HCC
Precigen, PAPZIMEOS, zopapogene imadenovec-drba, recurrent respiratory papillomatosis, RRP, CMS J-code J3404
Shionogi, RADICAVA, edaravone, amyotrophic lateral sclerosis, ALS, Tanabe Pharma America
NanoViricides, NV-387, measles, Rare Pediatric Disease Drug designation, orphan drug designation, priority review voucher, PRV
Amgen, TEPEZZA, teprotumumab-trbw, thyroid eye disease, TED, on-body injector, OBI
References
- https://neurocrine.gcs-web.com/news-releases/news-release-details/neurocrine-acquire-soleno-therapeutics-expanding-its
- https://www.biospace.com/press-releases/abbisko-therapeutics-fgfr4-inhibitor-irpagratinib-granted-orphan-drug-designation-by-ema-for-hepatocellular-carcinoma
- https://www.biospace.com/press-releases/precigen-reports-robust-uptake-of-new-drug-for-rare-respiratory-disease-first-quarter-revenue-expected-to-top-18-million
- https://www.businesswire.com/news/home/20260401952077/en/Shionogi-Completes-Acquisition-of-All-Rights-to-RADICAVA-edaravone
- https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/measles-rare-pediatric-disease-drug-designation-application-filed-for-1155499
- https://www.amgen.com/newsroom/press-releases/2026/04/amgen-announces-positive-topline-phase-3-results-for-subcutaneous-tepezza-in-adults-living-with-moderate-to-severe-active-thyroid-eye-disease